ARASENS data sends Bayer shares and Nubeqa forecast upwards

18 February 2022

German life sciences major Bayer (BAYN: DE) was trading nearly 2% higher on Friday afternoon after the presentation of positive data from the Phase III ARASENS trial of darolutamide (Nubeqa) in metastatic hormone-sensitive prostate cancer (mHSPC).

The results, presented at the at 2022 ASCO GU Cancers Symposium and published in The New England Journal of Medicine, showed that the use of darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly increased overall survival in patients with mHSPC compared to ADT plus docetaxel.

Darolutamide plus ADT and docetaxel significantly reduced the risk of death by 32.5% compared to ADT plus docetaxel.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK